Wanbury Limited (NSE:WANBURY)

Market Cap	9.27B +25.1%
Revenue (ttm)	6.58B +16.1%
Net Income	646.86M +47.3%
EPS	19.23 +49.9%
Shares Out	n/a
PE Ratio	14.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,726
Average Volume	277,940
Open	266.10
Previous Close	265.28
Day's Range	246.18 - 267.40
52-Week Range	154.01 - 329.70
Beta	-0.26
RSI	63.00
Earnings Date	Feb 5, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its n...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 1,382
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WANBURY

Financial Performance

In fiscal year 2025, Wanbury's revenue was 6.00 billion, an increase of 3.88% compared to the previous year's 5.78 billion. Earnings were 305.30 million, a decrease of -45.44%.